Drug switch trial aims to shield transplant patients from skin cancer return

This study tested whether switching kidney transplant patients who developed their first skin cancer from one type of anti-rejection drug (calcineurin inhibitors) to another (rapamycin) could prevent new skin cancers from forming over two years. It involved 77 patients who had received a kidney transplant and then developed a squamous cell carcinoma. Researchers compared the rate of new skin cancers between patients who switched medications and those who stayed on their original treatment.